Patent · US Active

Peptide analogues

US8653237B2 · kind B2 · utility

12Cited by
22References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 25, 2012
Grant dateFeb 18, 2014
Priority date
Expiry dateMay 25, 2032

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/645
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.